Lipid coated nanoparticles containing agents having low aqueous and lipid solubilities and methods thereof
Patent Number: US20150246137
Executive Summary:
General Description:
The present invention describes a stable vehicle for targeted delivery of drugs. Complexes can specifically target the bioactive compound to diseased cells, enhancing the effectiveness and minimizing the toxicity of the delivery system complexes. Provided in the invention are compositions that include delivery system complexes comprising a nano-precipitated bioactive compound, wherein the precipitate is encapsulated by a liposome or has at least a portion of its surface coated with a liposome.
Because the liposomes contain nano-precipitates of bioactive compounds, the liposomes are capable of formulating essentially insoluble forms of bioactive agents. Also described are methods for the treatment of a disease or an unwanted condition in a subject, wherein the methods comprise administering the delivery system complexes. The delivery system complexes can comprise any type of nano-precipitated bioactive compound, including but not limited to, polynucleotides, polypeptides, and drugs.
Scientific Progress:
Polymeric micelles incorporating cisplatin (CDDP) were prepared through the polymer-metal complex formation between CDDP and poly(ethylene glycol)-poly(glutamic acid) block copolymers, and their utility as a tumor-targeted drug delivery system was investigated. CDDP-incorporated micelles (CDDP/m) had a size of 28 nm with remarkably narrow distribution. (Ref 1)
Pre-clinical studies indicate that cisplatin encapsulated in STEALTH((R))liposomes (SPI-77) retains anti-tumour activity, but has a much reduced toxicity, compared to native cisplatin. (Ref 2)
Future Directions:
Strengths:
Patent Status:
Publications:
Inventor Bio: Leaf Huang
https://pharmacy.unc.edu/news/directory/leafh/
Executive Summary:
- Invention Type: Therapeutic
- Patent Status: Pending
- Patent Link: https://patents.google.com/patent/US20150246137
- Research Institute: University of North Carolina at Chapel Hill
- Disease Focus: Melanoma
- Basis of Invention: This invention is a delivery system complex comprising a nano-precipitated bioactive compound, wherein the nano-precipitate is encapsulated by a liposome or has at least a portion of its surface coated with a liposome
- How it works: Because the liposomes contain nano-precipitates of bioactive compounds, the liposomes are capable of utilization in formulating essentially insoluble forms of bioactive agents
- Lead Challenge Inventor: Leaf Huang
- Inventors: Shutao Guo, Leaf Huang, Srinivas Ramishetti
- Development Stage: In vivo data in mouse model
- Novelty:
- Claims to target any receptor/polynucleotide/siRNA transcript. The delivery system complexes can comprise any type of nano-precipitated bioactive compound, including but not limited to, polynucleotides, polypeptides, and drugs
- Clinical Applications:
- Effects shown in human melanoma mice
- Effects shown in human melanoma mice
General Description:
The present invention describes a stable vehicle for targeted delivery of drugs. Complexes can specifically target the bioactive compound to diseased cells, enhancing the effectiveness and minimizing the toxicity of the delivery system complexes. Provided in the invention are compositions that include delivery system complexes comprising a nano-precipitated bioactive compound, wherein the precipitate is encapsulated by a liposome or has at least a portion of its surface coated with a liposome.
Because the liposomes contain nano-precipitates of bioactive compounds, the liposomes are capable of formulating essentially insoluble forms of bioactive agents. Also described are methods for the treatment of a disease or an unwanted condition in a subject, wherein the methods comprise administering the delivery system complexes. The delivery system complexes can comprise any type of nano-precipitated bioactive compound, including but not limited to, polynucleotides, polypeptides, and drugs.
Scientific Progress:
Polymeric micelles incorporating cisplatin (CDDP) were prepared through the polymer-metal complex formation between CDDP and poly(ethylene glycol)-poly(glutamic acid) block copolymers, and their utility as a tumor-targeted drug delivery system was investigated. CDDP-incorporated micelles (CDDP/m) had a size of 28 nm with remarkably narrow distribution. (Ref 1)
Pre-clinical studies indicate that cisplatin encapsulated in STEALTH((R))liposomes (SPI-77) retains anti-tumour activity, but has a much reduced toxicity, compared to native cisplatin. (Ref 2)
Future Directions:
- Further studies are required to address the issue of reformulation of liposomally bound drugs
Strengths:
- Products are very stable in distilled water even in long-time storage, and exhibited a sustained drug release accompanied with the decay of the carrier itself in physiological saline
Patent Status:
- Publication date Sep 3, 2015
- Filing date Sep 26, 2013
- Priority date Sep 27, 2012
Publications:
- 1. Veal, G. J., Griffin, M. J., Price, E., Parry, A., Dick, G. S., Little, M. A., Yule, S. M., Morland, B., Estlin, E. J., Hale, J. P. et al. (2001) A phase I study in pediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin. Br J Cancer, 84, 1029-1035.
- 2. Nishiyama, N., Okazaki, S., Cabral, H., Miyamoto, M., Kato, Y., Sugiyama, Y., Nishio, K., Matsumura, Y. and Kataoka, K. (2003) Novel Cisplatin-Incorporated Polymeric Micelles Can Eradicate Solid Tumors in Mice. Cancer Research, 63, 8977-8983.
Inventor Bio: Leaf Huang
https://pharmacy.unc.edu/news/directory/leafh/